Migraine With Aura, Obesity, and a Request for Combined Hormonal Contraception
27-year-old G2P1 (one term cesarean for arrest of labor) presents for contraception. She has migraine with aura one to two times per month, BMI 36, and smokes eight cigarettes daily. Blood pressure is 124/78; she has no history of VTE, hypertension, or diabetes. She wants a combined oral contraceptive because her periods are heavy and painful and she has acne. She had an unintended pregnancy three years ago while taking pills, and she is wary of an IUD after a friend described a painful insertion. She asks specifically about the pill, patch, and vaginal ring, and says she wants something she can stop on her own.
1. Which of the methods she named are safe for her, and what alternatives should be offered? Explain the risk stratification.
Read the worked answer
The named methods-combined oral contraceptive, patch, and vaginal ring-all contain estrogen and share the same contraindications. Her migraine with aura places her in US MEC category 4 for combined hormonal contraception because of an unacceptable risk of ischemic stroke. The patch and ring are not safer alternatives; they deliver the same estrogen exposure. Her other factors add risk but do not change the category 4 designation: age under 35 with fewer than 15 cigarettes daily is category 2 for smoking alone, BMI ≥30 is category 2 for VTE risk, and her prior unintended pregnancy reflects effectiveness concerns rather than a medical contraindication.
Safe alternatives include the 52-mg levonorgestrel IUD, the etonogestrel implant, the copper IUD, and depot medroxyprogesterone acetate (DMPA). The LNG-IUD is particularly attractive because it is category 1 for her and treats heavy menstrual bleeding and dysmenorrhea. The copper IUD is category 1 but may worsen bleeding. The implant is category 1/2 and highly effective. DMPA is category 1/2 and may reduce dysmenorrhea, but unscheduled bleeding and bone mineral density considerations should be discussed. Emergency contraception should also be reviewed.
2. She says she cannot tolerate the idea of an IUD and asks for DMPA because a friend told her it stops periods. How do you counsel her and document the decision?
Read the worked answer
Counseling should correct the expectation that DMPA reliably causes amenorrhea. Amenorrhea occurs in a minority of users at one year and becomes more common with continued use, but many users have unpredictable spotting, especially early. DMPA may improve dysmenorrhea and is not estrogen-containing, so her aura is not a contraindication. Discuss weight gain, delayed return to fertility after discontinuation, and bone mineral density labeling; for a 27-year-old with no other risk factors, DMPA remains a reasonable option with counseling, and self-injection can be considered if she is motivated.
Because she declined the IUD and has a history of contraceptive failure, document that she was counseled about the superior effectiveness of the implant and IUDs, that DMPA requires adherence to a 12- to 13-week schedule, and that she understands unscheduled bleeding. A shared decision-making note should capture her values-control, privacy, and fear of insertion-rather than simply listing methods. Provide emergency contraception guidance and a plan for follow-up if bleeding is intolerable.
3. She instead chooses the etonogestrel implant but returns at 7 months with 3 weeks of daily spotting and requests removal. What is your approach?
Read the worked answer
First confirm the implant is palpable and rule out pregnancy with a urine or serum hCG. Unscheduled bleeding is the most common reason for implant discontinuation and is often self-limited, so reassurance and a short period of observation are appropriate if she is otherwise well. NSAIDs can be tried, but evidence for benefit is limited. A short course of estrogen-containing medication is often used for implant-associated bleeding, but it is contraindicated here because of her migraine with aura; prescribing a combined oral contraceptive would be a serious error.
If bleeding persists and she wants it stopped, options include removing the implant and placing an LNG-IUD, which is likely to improve both bleeding and dysmenorrhea, or switching to DMPA with counseling about unpredictable bleeding. Do not dismiss her request for removal; respect autonomy and document the discussion. If she chooses removal, provide a bridging method immediately and confirm a negative pregnancy test before placing a new device.